Nuclear pore dysfunction and disease: a complex opportunity

References

• Webster BM, Lusk CP. Border safety: quality control at the nuclear envelope. Trends Cell Biol. 2016;26:29–30. doi:10.1016/j.tcb.2015.08.002
   PubMed Web of Science ®Google Scholar
• Robijns J, Houthaeve G, Braeckmans K, et al. Loss of nuclear envelope integrity in aging and disease. Int Rev Cell Mol Biol. 2018;336:205–222.
   PubMed Web of Science ®Google Scholar
• Lindenboim L, Zohar H, Worman HJ, et al. The nuclear envelope: target and mediator of the apoptotic process. Cell Death Discov. 2020;6(1):29. doi: 10.1038/s41420-020-0256-5
   PubMed Web of Science ®Google Scholar
• Gauthier BR, Comaills V. Nuclear envelope integrity in health and disease: consequences on genome instability and inflammation. IJMS. 2021;22(14):7281. doi: 10.3390/ijms22147281
   Google Scholar
• Metuzals J, Robitaille Y, Houghton S, et al. Paired helical filaments and the cytoplasmic-nuclear interface in Alzheimer’s disease. J Neurocytol. 1988;17(6):827–833. doi: 10.1007/BF01216709
   PubMedGoogle Scholar
• Lee HG, Ueda M, Miyamoto Y, et al. Aberrant localization of importin α1 in hippocampal neurons in alzheimer disease. Brain Res. 2006;1124(1):1–4. doi: 10.1016/j.brainres.2006.09.084
   PubMedGoogle Scholar
• Sheffield LG, Miskiewicz HB, Tannenbaum LB, et al. Nuclear pore complex proteins in Alzheimer disease. J Neuropathol Exp Neurol. 2006;65(1):45–54. doi: 10.1097/01.jnen.0000195939.40410.08
   PubMed Web of Science ®Google Scholar
• Mastroeni D, Chouliaras L, Grover A, et al. Reduced RAN expression and disrupted transport between cytoplasm and nucleus; a key event in Alzheimer’s disease pathophysiology. PLoS One. 2013;8(1):e53349. doi: 10.1371/journal.pone.0053349
   PubMed Web of Science ®Google Scholar
• Eftekharzadeh B, Daigle JG, Kapinos LE, et al. Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease. Neuron. 2018;99(5):925–940 e927. doi: 10.1016/j.neuron.2018.07.039
   PubMed Web of Science ®Google Scholar
• Leone L, Colussi C, Gironi K, et al. Altered Nup153 expression impairs the function of cultured hippocampal neural stem cells isolated from a mouse Model of Alzheimer’s disease. Mol Neurobiol. 2019;56(8):5934–5949. doi: 10.1007/s12035-018-1466-1
   PubMed Web of Science ®Google Scholar
• Diez L, Kapinos LE, Hochmair J, et al. Phosphorylation but not oligomerization drives the accumulation of Tau with Nucleoporin Nup98. Int J Mol Sci. 2022;23(7):3495. doi: 10.3390/ijms23073495
   PubMed Web of Science ®Google Scholar
• Dickson JR, Frosch MP, Hyman BT. Altered localization of nucleoporin 98 in primary tauopathies. Brain Commun. 2023;5(1):fcac334. doi: 10.1093/braincomms/fcac334
   PubMedGoogle Scholar
• Donnaloja F, Limonta E, Mancosu C, et al. Unravelling the mechanotransduction pathways in Alzheimer’s disease. J Biol Eng. 2023;17(1):22. doi: 10.1186/s13036-023-00336-w
   PubMed Web of Science ®Google Scholar
• Nag N, Tripathi T. Tau–FG-nucleoporin98 interaction and impaired nucleocytoplasmic transport in Alzheimer’s disease. Brief Funct Genomics. 2023;22(2):161–167. doi: 10.1093/bfgp/elac022
   PubMed Web of Science ®Google Scholar
• Um JW, Min DS, Rhim H, et al. Parkin ubiquitinates and promotes the degradation of RanBP2. J Biol Chem. 2006;281(6):3595–3603. doi: 10.1074/jbc.M504994200
   PubMed Web of Science ®Google Scholar
• Alegre-Abarrategui J, Ansorge O, Esiri M, et al. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson’s disease. Neuropathol Appl Neurobiol. 2008;34:272–283. doi:10.1111/j.1365-2990.2007.00888.x
   PubMed Web of Science ®Google Scholar
• Kokoulina P, Rohn TT. Caspase-cleaved transactivation response DNA-binding protein 43 in Parkinson’s disease and dementia with Lewy bodies. Neurodegener Dis. 2010;7(4):243–250. doi: 10.1159/000287952
   PubMed Web of Science ®Google Scholar
• Liu GH, Qu J, Suzuki K, et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature. 2012;491(7425):603–607. doi: 10.1038/nature11557
   PubMed Web of Science ®Google Scholar
• Shani V, Safory H, Szargel R, et al. Physiological and pathological roles of LRRK2 in the nuclear envelope integrity. Hum Mol Genet. 2019;28:3982–3996. doi: 10.1093/hmg/ddz245
   PubMed Web of Science ®Google Scholar
• Chen X, Xie C, Tian W, et al. Parkinson’s disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging. Mol Neurodegener. 2020;15(1):12. doi: 10.1186/s13024-020-00360-0
   PubMed Web of Science ®Google Scholar
• Gasset-Rosa F, Chillon-Marinas C, Goginashvili A, et al. Polyglutamine-Expanded Huntingtin Exacerbates Age-Related Disruption of Nuclear Integrity and Nucleocytoplasmic Transport. Neuron. 2017;94(1):48–57.e44. doi: 10.1016/j.neuron.2017.03.027
   PubMed Web of Science ®Google Scholar
• Grima JC, Daigle JG, Arbez N, et al. Mutant huntingtin disrupts the nuclear pore complex. Neuron. 2017;94(1):93–107 e106. doi: 10.1016/j.neuron.2017.03.023
   PubMed Web of Science ®Google Scholar
• Lange J, Wood-Kaczmar A, Ali A, et al. Mislocalization of nucleocytoplasmic transport proteins in human Huntington’s disease PSC-Derived striatal neurons. Front Cell Neurosci. 2021;15:742763. doi: 10.3389/fncel.2021.742763
   PubMed Web of Science ®Google Scholar
• Pesiridis GS, Lee VM, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet. 2009;18(R2):R156–R162. doi: 10.1093/hmg/ddp303
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Kocerha J, Finch N, et al. De Novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat. 2010;31(5):E1377–E1389. doi: 10.1002/humu.21241
   PubMed Web of Science ®Google Scholar
• Dormann D, Rodde R, Edbauer D, et al. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29(16):2841–2857. doi: 10.1038/emboj.2010.143
   PubMed Web of Science ®Google Scholar
• Ito D, Seki M, Tsunoda Y, et al. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. Ann Neurol. 2011;69(1):152–162. doi: 10.1002/ana.22246
   PubMed Web of Science ®Google Scholar
• Niu C, Zhang J, Gao F, et al. FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS. PLoS One. 2012;7(10):e47056. doi: 10.1371/journal.pone.0047056
   PubMed Web of Science ®Google Scholar
• Zhang ZC, Chook YM. Structural and energetic basis of ALS-causing mutations in the atypical proline–tyrosine nuclear localization signal of the fused in sarcoma protein (FUS). Proc Natl Acad Sci, USA. 2012;109(30):12017–12021. doi: 10.1073/pnas.1207247109
   PubMed Web of Science ®Google Scholar
• Baron DM, Kaushansky LJ, Ward CL, et al. Amyotrophic lateral sclerosis-linked FUS/TLS alters stress granule assembly and dynamics. Mol Neurodegener. 2013;8(1):30. doi: 10.1186/1750-1326-8-30
   PubMedGoogle Scholar
• Kim HJ, Kim NC, Wang Y-D, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467–473. doi: 10.1038/nature11922
   PubMed Web of Science ®Google Scholar
• Vance C, Scotter EL, Nishimura AL, et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum Mol Genet. 2013;22(13):2676–2688. doi: 10.1093/hmg/ddt117
   PubMed Web of Science ®Google Scholar
• Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56–61. doi: 10.1038/nature14973
   PubMed Web of Science ®Google Scholar
• Chou CC, Zhang Y, Umoh ME, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21(2):228–239. doi: 10.1038/s41593-017-0047-3
   PubMed Web of Science ®Google Scholar
• Guo L, Kim HJ, Wang H, et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-Binding proteins with prion-like domains. Cell. 2018;173(3):677–692 e620. doi: 10.1016/j.cell.2018.03.002
   PubMed Web of Science ®Google Scholar
• Zhang K, Daigle JG, Cunningham KM, et al. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173(4):958–971 e917. doi: 10.1016/j.cell.2018.03.025
   PubMed Web of Science ®Google Scholar
• Aizawa H, Yamashita T, Kato H, et al. Impaired nucleoporins are present in sporadic amyotrophic lateral sclerosis motor neurons that exhibit mislocalization of the 43-kDa TAR DNA-Binding protein. J Clin Neurol. 2019;15(1):62–67. doi: 10.3988/jcn.2019.15.1.62
   PubMed Web of Science ®Google Scholar
• Gasset-Rosa F, Lu S, Yu H, et al. Cytoplasmic TDP-43 De-mixing Independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102(2):339–357.e7. doi: 10.1016/j.neuron.2019.02.038
   PubMed Web of Science ®Google Scholar
• Giampetruzzi A, Danielson EW, Gumina V, et al. Modulation of actin polymerization affects nucleocytoplasmic transport in multiple forms of amyotrophic lateral sclerosis. Nat Commun. 2019;10(1):3827. doi: 10.1038/s41467-019-11837-y
   PubMedGoogle Scholar
• Tyzack GE, Luisier R, Taha DM, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142(9):2572–2580. doi: 10.1093/brain/awz217
   PubMedGoogle Scholar
• Coyne AN, Zaepfel BL, Hayes L, et al. G4C2 repeat RNA initiates a POM121-mediated reduction in specific nucleoporins in C9orf72 ALS/FTD. Neuron. 2020;107(6):1124–1140 e1111. doi: 10.1016/j.neuron.2020.06.027
   PubMed Web of Science ®Google Scholar
• Hayes LR, Duan L, Bowen K, et al. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. Elife. 2020;9. doi: 10.7554/eLife.51685
   Web of Science ®Google Scholar
• Hutten S, Usluer S, Bourgeois B, et al. Nuclear import receptors directly bind to Arginine-Rich Dipeptide repeat proteins and suppress their pathological interactions. Cell Rep. 2020;33(12):108538. doi: 10.1016/j.celrep.2020.108538
   PubMed Web of Science ®Google Scholar
• Coyne AN, Baskerville V, Zaepfel BL, et al. Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Sci Transl Med. 2021;13(604). doi: 10.1126/scitranslmed.abe1923
   Web of Science ®Google Scholar
• Lin YC, Kumar MS, Ramesh N, et al. Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nat Neurosci. 2021;24(8):1077–1088. doi: 10.1038/s41593-021-00859-9
   PubMed Web of Science ®Google Scholar
• Dubey SK, Maulding K, Sung H, et al. Nucleoporins are degraded via upregulation of ESCRT-III/Vps4 complex in Drosophila models of C9-ALS/FTD. Cell Rep. 2022;40(12):111379. doi: 10.1016/j.celrep.2022.111379
   PubMed Web of Science ®Google Scholar
• Gleixner AM, Verdone BM, Otte CG, et al. NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility. Nat Commun. 2022;13(1):3380. doi: 10.1038/s41467-022-31098-6
   PubMed Web of Science ®Google Scholar
• Khalil B, Chhangani D, Wren MC, et al. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy. Mol Neurodegener. 2022;17(1):80. doi: 10.1186/s13024-022-00585-1
   PubMed Web of Science ®Google Scholar
• Vanneste J, Vercruysse T, Boeynaems S, et al. Cellular stress induces nucleocytoplasmic transport deficits independent of stress granules. Biomedicines. 2022;10(5):1057. doi: 10.3390/biomedicines10051057
   PubMed Web of Science ®Google Scholar
• Spead O, Zaepfel BL, Rothstein JD. Nuclear Pore Dysfunction in Neurodegeneration. Neurotherapeutics. 2022;19(4):1050–1060. doi: 10.1007/s13311-022-01293-w
   PubMed Web of Science ®Google Scholar
• Anderson EN, Morera AA, Kour S, et al. Traumatic injury compromises nucleocytoplasmic transport and leads to TDP-43 pathology. Elife. 2021;10. doi: 10.7554/eLife.67587
   Web of Science ®Google Scholar
• D’Angelo MA, Raices M, Panowski SH, et al. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell. 2009;136(2):284–295. doi: 10.1016/j.cell.2008.11.037
   PubMed Web of Science ®Google Scholar
• Rempel IL, Crane MM, Thaller DJ, et al. Age-dependent deterioration of nuclear pore assembly in mitotic cells decreases transport dynamics. Elife. 2019;8. doi: 10.7554/eLife.48186
   PubMed Web of Science ®Google Scholar
• Park JH, Ryu SJ, Kim BJ, et al. Disruption of nucleocytoplasmic trafficking as a cellular senescence driver. Exp Mol Med. 2021;53(6):1092–1108. doi: 10.1038/s12276-021-00643-6
   PubMed Web of Science ®Google Scholar
• Lin DH, Hoelz A. The structure of the nuclear pore complex (an update). Annu Rev Biochem. 2019;88(1):725–783. doi: 10.1146/annurev-biochem-062917-011901
   PubMed Web of Science ®Google Scholar
• Maul GG, Deaven L. Quantitative determination of nuclear pore complexes in cycling cells with differing DNA content. J Cell Bio. 1977;73(3):748–760. doi: 10.1083/jcb.73.3.748
   PubMed Web of Science ®Google Scholar
• Garcia-Segura LM, Lafarga M, Berciano MT, et al. Distribution of nuclear pores and chromatin organization in neurons and glial cells of the rat cerebellar cortex. J Comp Neurol. 1989;290(3):440–450. doi: 10.1002/cne.902900311
   PubMed Web of Science ®Google Scholar
• Jamali T, Jamali Y, Mehrbod M, et al. Nuclear pore complex: biochemistry and biophysics of nucleocytoplasmic transport in health and disease. Int Rev Cell Mol Biol. 2011;287:233–286.
   PubMed Web of Science ®Google Scholar
• Bley CJ, Nie S, Mobbs GW, et al. Architecture of the cytoplasmic face of the nuclear pore. Science. 2022;376(6598):eabm9129. doi: 10.1126/science.abm9129
   PubMed Web of Science ®Google Scholar
• Fontana P, Dong Y, Pi X, et al. Structure of cytoplasmic ring of nuclear pore complex by integrative cryo-EM and AlphaFold. Science. 2022;376(6598):eabm9326. doi: 10.1126/science.abm9326
   PubMed Web of Science ®Google Scholar
• Petrovic S, Samanta D, Perriches T, et al. Architecture of the linker-scaffold in the nuclear pore. Science. 2022;376(6598):eabm9798. doi: 10.1126/science.abm9798
   PubMed Web of Science ®Google Scholar
• Lutzmann M, Kunze R, Buerer A, et al. Modular self-assembly of a Y-shaped multiprotein complex from seven nucleoporins. EMBO J. 2002;21(3):387–397. doi: 10.1093/emboj/21.3.387
   PubMed Web of Science ®Google Scholar
• Frey S, Gorlich D. A saturated FG-repeat hydrogel can reproduce the permeability properties of nuclear pore complexes. Cell. 2007;130(3):512–523. doi: 10.1016/j.cell.2007.06.024
   PubMed Web of Science ®Google Scholar
• Patel SS, Belmont BJ, Sante JM, et al. Natively unfolded nucleoporins gate protein diffusion across the nuclear pore complex. Cell. 2007;129(1):83–96. doi: 10.1016/j.cell.2007.01.044
   PubMed Web of Science ®Google Scholar
• Schmidt HB, Görlich D. Nup98 FG domains from diverse species spontaneously phase-separate into particles with nuclear pore-like permselectivity. Elife. 2015;4. doi: 10.7554/eLife.04251
   Web of Science ®Google Scholar
• Li C, Goryaynov A, Yang W. The selective permeability barrier in the nuclear pore complex. Nucleus. 2016;7(5):430–446. doi: 10.1080/19491034.2016.1238997
   PubMed Web of Science ®Google Scholar
• Ng SC, Biswas A, Huyton T, et al. Barrier properties of Nup98 FG phases ruled by FG motif identity and inter-FG spacer length. Nat Commun. 2023;14(1):747. doi: 10.1038/s41467-023-36331-4
   PubMed Web of Science ®Google Scholar
• Frey S, Richter RP, Gorlich D. FG-rich repeats of nuclear pore proteins form a three-dimensional meshwork with hydrogel-like properties. Science. 2006;314(5800):815–817. doi: 10.1126/science.1132516
   PubMed Web of Science ®Google Scholar
• Hulsmann BB, Labokha AA, Gorlich D. The permeability of reconstituted nuclear pores provides direct evidence for the selective phase model. Cell. 2012;150(4):738–751. doi: 10.1016/j.cell.2012.07.019
   PubMed Web of Science ®Google Scholar
• Celetti G, Paci G, Caria J, et al. The liquid state of FG-nucleoporins mimics permeability barrier properties of nuclear pore complexes. J Cell Bio. 2020;219(1). doi: 10.1083/jcb.201907157
   PubMed Web of Science ®Google Scholar
• Denning DP, Patel SS, Uversky V, et al. Disorder in the nuclear pore complex: the FG repeat regions of nucleoporins are natively unfolded. Proc Natl Acad Sci, USA. 2003;100(5):2450–2455. doi: 10.1073/pnas.0437902100
   PubMed Web of Science ®Google Scholar
• Yu M, Heidari M, Mikhaleva S, et al. Visualizing the disordered nuclear transport machinery in situ. Nature. 2023;617(7959):162–169. doi: 10.1038/s41586-023-05990-0
   PubMed Web of Science ®Google Scholar
• Kalita J, Kapinos LE, Zheng T, et al. Karyopherin enrichment and compensation fortifies the nuclear pore complex against nucleocytoplasmic leakage. J Cell Bio. 2022;221(3). doi: 10.1083/jcb.202108107
   PubMed Web of Science ®Google Scholar
• Ibanez de Opakua A, Geraets JA, Frieg B, et al. Molecular interactions of FG nucleoporin repeats at high resolution. Nat Chem. 2022;14(11):1278–1285. doi: 10.1038/s41557-022-01035-7
   PubMed Web of Science ®Google Scholar
• Kapinos LE, Huang B, Rencurel C, et al. Karyopherins regulate nuclear pore complex barrier and transport function. J Cell Bio. 2017;216(11):3609–3624. doi: 10.1083/jcb.201702092
   PubMed Web of Science ®Google Scholar
• Wälde S, Thakar K, Hutten S, et al. The nucleoporin Nup358/RanBP2 promotes nuclear import in a cargo- and transport receptor-specific manner. Traffic. 2012;13(2):218–233. doi: 10.1111/j.1600-0854.2011.01302.x
   PubMed Web of Science ®Google Scholar
• Lemaître C, Fischer B, Kalousi A, et al. The nucleoporin 153, a novel factor in double-strand break repair and DNA damage response. Oncogene. 2012;31(45):4803–4809. doi: 10.1038/onc.2011.638
   PubMed Web of Science ®Google Scholar
• Moudry P, Lukas C, Macurek L, et al. Nucleoporin NUP153 guards genome integrity by promoting nuclear import of 53BP1. Cell Death Differ. 2012;19(5):798–807. doi: 10.1038/cdd.2011.150
   PubMed Web of Science ®Google Scholar
• Waldmann I, Spillner C, Kehlenbach RH. The nucleoporin-like protein NLP1 (hCG1) promotes CRM1-dependent nuclear protein export. J Cell Sci. 2012;125(1):144–154. doi: 10.1242/jcs.090316
   PubMed Web of Science ®Google Scholar
• Gozalo A, Duke A, Lan Y, et al. Core components of the nuclear pore bind distinct states of chromatin and contribute to polycomb repression. Mol Cell. 2020;77(1):67–81.e67. doi: 10.1016/j.molcel.2019.10.017
   PubMed Web of Science ®Google Scholar
• Kadota S, Ou J, Shi Y, et al. Nucleoporin 153 links nuclear pore complex to chromatin architecture by mediating CTCF and cohesin binding. Nat Commun. 2020;11(1):2606. doi: 10.1038/s41467-020-16394-3
   PubMed Web of Science ®Google Scholar
• Ibarra A, Benner C, Tyagi S, et al. Nucleoporin-mediated regulation of cell identity genes. Genes Dev. 2016;30(20):2253–2258. doi: 10.1101/gad.287417.116
   PubMed Web of Science ®Google Scholar
• Labade AS, Karmodiya K, Sengupta K. HOXA repression is mediated by nucleoporin Nup93 assisted by its interactors Nup188 and Nup205. Epigenet Chromatin. 2016;9(1):54. doi: 10.1186/s13072-016-0106-0
   PubMedGoogle Scholar
• Zhu X, Qi C, Wang R, et al. Acute depletion of human core nucleoporin reveals direct roles in transcription control but dispensability for 3D genome organization. Cell Rep. 2022;41(5):111576. doi: 10.1016/j.celrep.2022.111576
   PubMed Web of Science ®Google Scholar
• Hubert T, Vandekerckhove J, Gettemans J. Exo70-mediated recruitment of nucleoporin Nup62 at the leading edge of migrating cells is required for cell migration. Traffic. 2009;10(9):1257–1271. doi: 10.1111/j.1600-0854.2009.00940.x
   PubMed Web of Science ®Google Scholar
• Joseph J, Dasso M. The nucleoporin Nup358 associates with and regulates interphase microtubules. FEBS Lett. 2008;582(2):190–196. doi: 10.1016/j.febslet.2007.11.087
   PubMed Web of Science ®Google Scholar
• Makise M, Uchimura R, Higashi K, et al. Overexpression of the nucleoporin Nup88 stimulates migration and invasion of HeLa cells. Histochem Cell Biol. 2021;156(5):409–421. doi: 10.1007/s00418-021-02020-w
   PubMed Web of Science ®Google Scholar
• Nataraj NB, Noronha A, Lee JS, et al. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Rep. 2022;38(8):110418. doi: 10.1016/j.celrep.2022.110418
   PubMed Web of Science ®Google Scholar
• Kirsh O, Seeler JS, Pichler A, et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 2002;21(11):2682–2691. doi: 10.1093/emboj/21.11.2682
   PubMed Web of Science ®Google Scholar
• Gloerich M, Vliem MJ, Prummel E, et al. The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity. J Cell Bio. 2011;193(6):1009–1020. doi: 10.1083/jcb.201011126
   PubMed Web of Science ®Google Scholar
• Faria AM, Levay A, Wang Y, et al. The nucleoporin Nup96 is required for proper expression of interferon-regulated proteins and functions. Immunity. 2006;24(3):295–304. doi: 10.1016/j.immuni.2006.01.014
   PubMed Web of Science ®Google Scholar
• Monwan W, Kawasaki T, Hasan MZ, et al. Identification of nucleoporin 93 (Nup93) that mediates antiviral innate immune responses. Biochem Biophys Res Commun. 2020;521(4):1077–1082. doi: 10.1016/j.bbrc.2019.11.035
   PubMed Web of Science ®Google Scholar
• Funasaka T, Tsuka E, Wong RW. Regulation of autophagy by nucleoporin Tpr. Sci Rep. 2012;2(1):878. doi: 10.1038/srep00878
   PubMedGoogle Scholar
• Wang SM, Wu H-E, Yasui Y, et al. Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine. Autophagy. 2023;19(1):126–151. doi: 10.1080/15548627.2022.2063003
   PubMed Web of Science ®Google Scholar
• Chou YY, Upadhyayula S, Houser J, et al. Inherited nuclear pore substructures template post-mitotic pore assembly. Dev Cell. 2021;56(12):1786–1803.e1789. doi: 10.1016/j.devcel.2021.05.015
   PubMed Web of Science ®Google Scholar
• Kutay U, Jühlen R, Antonin W. Mitotic disassembly and reassembly of nuclear pore complexes. Trends Cell Biol. 2021;31(12):1019–1033. doi: 10.1016/j.tcb.2021.06.011
   PubMed Web of Science ®Google Scholar
• Otsuka S, Tempkin JOB, Zhang W, et al. A quantitative map of nuclear pore assembly reveals two distinct mechanisms. Nature. 2023;613(7944):575–581. doi: 10.1038/s41586-022-05528-w
   PubMed Web of Science ®Google Scholar
• Kaganovich D, Kopito R, Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature. 2008;454(7208):1088–1095. doi: 10.1038/nature07195
   PubMed Web of Science ®Google Scholar
• Miller SB, Ho C-T, Winkler J, et al. Compartment-specific aggregases direct distinct nuclear and cytoplasmic aggregate deposition. EMBO J. 2015;34(6):778–797. doi: 10.15252/embj.201489524
   PubMed Web of Science ®Google Scholar
• Koch BA, Staley E, Jin H, et al. The ESCRT-III complex is required for nuclear pore complex sequestration and regulates gamete replicative lifespan in budding yeast meiosis. Nucleus. 2020;11(1):219–236. doi: 10.1080/19491034.2020.1812872
   PubMed Web of Science ®Google Scholar
• Rujano MA, Bosveld F, Salomons FA, et al. Polarised asymmetric inheritance of accumulated protein damage in higher eukaryotes. PLoS Biol. 2006;4(12):e417. doi: 10.1371/journal.pbio.0040417
   PubMed Web of Science ®Google Scholar
• Toyama BH, Arrojo e Drigo R, Lev-Ram V, et al. Visualization of long-lived proteins reveals age mosaicism within nuclei of postmitotic cells. J Cell Bio. 2019;218(2):433–444. doi: 10.1083/jcb.201809123
   PubMed Web of Science ®Google Scholar
• Dultz E, Wojtynek M, Medalia O, et al. The nuclear pore complex: birth, life, and death of a cellular behemoth. Cells. 2022;11(9):1456. doi: 10.3390/cells11091456
   PubMed Web of Science ®Google Scholar
• Kuiper EFE, Gallardo P, Bergsma T, et al. The chaperone DNAJB6 surveils FG-nucleoporins and is required for interphase nuclear pore complex biogenesis. Nat Cell Biol. 2022;24(11):1584–1594. doi: 10.1038/s41556-022-01010-x
   PubMed Web of Science ®Google Scholar
• Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron. 2005;48(6):923–932. doi: 10.1016/j.neuron.2005.11.010
   PubMed Web of Science ®Google Scholar
• Rampello AJ, Laudermilch E, Vishnoi N, et al. Torsin ATPase deficiency leads to defects in nuclear pore biogenesis and sequestration of MLF2. J Cell Bio. 2020;219(6). doi: 10.1083/jcb.201910185
   PubMed Web of Science ®Google Scholar
• Lowe AR, Tang JH, Yassif J, et al. Importin-β modulates the permeability of the nuclear pore complex in a Ran-dependent manner. Elife. 2015;4. doi: 10.7554/eLife.04052
   PubMed Web of Science ®Google Scholar
• Thaller DJ, Allegretti M, Borah S, et al. An ESCRT-LEM protein surveillance system is poised to directly monitor the nuclear envelope and nuclear transport system. Elife. 2019;8. doi: 10.7554/eLife.45284
   Web of Science ®Google Scholar
• Webster BM, Colombi P, Jäger J, et al. Surveillance of nuclear pore complex assembly by ESCRT-III/Vps4. Cell. 2014;159(2):388–401. doi: 10.1016/j.cell.2014.09.012
   PubMed Web of Science ®Google Scholar
• Kagias K, Nehammer C, Pocock R. Neuronal responses to physiological stress. Front Genet. 2012;3:222. doi:10.3389/fgene.2012.00222
   PubMedGoogle Scholar
• Toyama BH, Savas J, Park S, et al. Identification of long-lived proteins reveals exceptional stability of essential cellular structures. Cell. 2013;154(5):971–982. doi: 10.1016/j.cell.2013.07.037
   PubMed Web of Science ®Google Scholar
• Hakhverdyan Z, Molloy KR, Keegan S, et al. Dissecting the structural dynamics of the nuclear pore complex. Mol Cell. 2021;81(1):153–165.e157. doi: 10.1016/j.molcel.2020.11.032
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu KM, Yang L, et al. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1):28. doi: 10.1186/s13024-022-00533-z
   PubMed Web of Science ®Google Scholar
• Paonessa F, Evans LD, Solanki R, et al. Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia. Cell Rep. 2019;26(3):582–593.e585. doi: 10.1016/j.celrep.2018.12.085
   PubMed Web of Science ®Google Scholar
• Candia RF, Cohen LS, Morozova V, et al. Importin-Mediated pathological tau nuclear translocation causes disruption of the nuclear lamina, TDP-43 mislocalization and cell death. Front Mol Neurosci. 2022;15:888420. doi:10.3389/fnmol.2022.888420
   PubMed Web of Science ®Google Scholar
• Wang H, Wang R, Xu S, et al. Transcription factor EB is selectively reduced in the nuclear fractions of Alzheimer’s and amyotrophic lateral sclerosis brains. Neurosci J. 2016;2016:4732837. doi:10.1155/2016/4732837
   PubMedGoogle Scholar
• Montalbano M, McAllen S, Puangmalai N, et al. RNA-binding proteins Musashi and tau soluble aggregates initiate nuclear dysfunction. Nat Commun. 2020;11(1):4305. doi: 10.1038/s41467-020-18022-6
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat Rev Neurosci. 2007;8(7):499–509. doi: 10.1038/nrn2168
   PubMed Web of Science ®Google Scholar
• Barucker C, Harmeier A, Weiske J, et al. Nuclear translocation uncovers the amyloid peptide Aβ42 as a regulator of gene transcription. J Biol Chem. 2014;289(29):20182–20191. doi: 10.1074/jbc.M114.564690
   PubMed Web of Science ®Google Scholar
• Bailey JA, Maloney B, Ge YW, et al. Functional activity of the novel Alzheimer’s amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. Gene. 2011;488:13–22. doi:10.1016/j.gene.2011.06.017
   PubMed Web of Science ®Google Scholar
• Gezen-Ak D, Atasoy IL, Candaş E, et al. Vitamin D receptor regulates amyloid beta 1–42 production with protein disulfide isomerase A3. ACS Chem Neurosci. 2017;8(10):2335–2346. doi: 10.1021/acschemneuro.7b00245
   PubMed Web of Science ®Google Scholar
• Pryor NE, Moss MA, Hestekin CN. Unraveling the early events of amyloid-β protein (Aβ) aggregation: techniques for the determination of Aβ aggregate size. Int J Mol Sci. 2012;13(3):3038–3072. doi: 10.3390/ijms13033038
   PubMed Web of Science ®Google Scholar
• Kouli A, Torsney KM, Kuan WL. Chapter 1: Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson’s disease: pathogenesis and clinical aspect. Stoker, TB, and Greenland JC, editors. Brisbane, Australia: Codon Publications; 2018. p. 3–26.
   Google Scholar
• Xia Q, Liao L, Cheng D, et al. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008;13 :3850–3856. doi: 10.2741/2973
   PubMed Web of Science ®Google Scholar
• McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25:24–34. doi:10.1111/ene.13413
   PubMed Web of Science ®Google Scholar
• Suhr ST, Senut M-C, Whitelegge JP, et al. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Bio. 2001;153(2):283–294. doi: 10.1083/jcb.153.2.283
   PubMed Web of Science ®Google Scholar
• Liu KY, Shyu YC, Barbaro BA, et al. Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington’s disease. Hum Mol Genet. 2015;24:1602–1616. doi: 10.1093/hmg/ddu574
   PubMed Web of Science ®Google Scholar
• Desmond CR, Atwal RS, Xia J, et al. Identification of a karyopherin β1/β2 Proline-Tyrosine nuclear localization signal in huntingtin protein. J Biol Chem. 2012;287(47):39626–39633. doi: 10.1074/jbc.M112.412379
   PubMed Web of Science ®Google Scholar
• Shirasaki DI, Greiner E, Al-Ramahi I, et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron. 2012;75(1):41–57. doi: 10.1016/j.neuron.2012.05.024
   PubMed Web of Science ®Google Scholar
• Langfelder P, Cantle JP, Chatzopoulou D, et al. Integrated genomics and proteomics define huntingtin CAG length–dependent networks in mice. Nat Neurosci. 2016;19(4):623–633. doi: 10.1038/nn.4256
   PubMed Web of Science ®Google Scholar
• Hofweber M, Hutten S, Bourgeois B, et al. Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell. 2018;173(3):706–719 e713. doi: 10.1016/j.cell.2018.03.004
   PubMed Web of Science ®Google Scholar
• Qamar S, Wang G, Randle SJ, et al. FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation-π interactions. Cell. 2018;173(3):720–734 e715. doi: 10.1016/j.cell.2018.03.056
   PubMed Web of Science ®Google Scholar
• Baade I, Hutten S, Sternburg EL, et al. The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors. J Biol Chem. 2021;296:100659. doi: 10.1016/j.jbc.2021.100659
   PubMed Web of Science ®Google Scholar
• Beijer D, Kim HJ, Guo L, et al. Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI Insight. 2021;6(14). doi: 10.1172/jci.insight.148363
   PubMed Web of Science ®Google Scholar
• Fare CM, Rhine K, Lam A, et al. A minimal construct of nuclear-import receptor karyopherin-β2 defines the regions critical for chaperone and disaggregation activity. J Biol Chem. 2022;102806(2):102806. doi: 10.1016/j.jbc.2022.102806
   Google Scholar
• Kim HJ, Mohassel P, Donkervoort S, et al. Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nat Commun. 2022;13(1):2306. doi: 10.1038/s41467-022-30015-1
   PubMed Web of Science ®Google Scholar
• Woerner AC, Frottin F, Hornburg D, et al. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA. Science. 2016;351(6269):173–176. doi: 10.1126/science.aad2033
   PubMed Web of Science ®Google Scholar
• Cook CN, Wu Y, Odeh HM, et al. C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy. Sci Transl Med. 2020;12(559). doi: 10.1126/scitranslmed.abb3774
   Web of Science ®Google Scholar
• de Mezer M, Wojciechowska M, Napierala M, et al. Mutant CAG repeats of huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference. Nucleic Acids Res. 2011;39(9):3852–3863. doi: 10.1093/nar/gkq1323
   PubMed Web of Science ®Google Scholar
• Bañez-Coronel M, et al. A pathogenic mechanism in Huntington’s disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet. 2012;8:e1002481. doi: 10.1371/journal.pgen.1002481
   PubMed Web of Science ®Google Scholar
• Rué L, Bañez-Coronel M, Creus-Muncunill J, et al. Targeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels. J Clin Invest. 2016;126(11):4319–4330. doi: 10.1172/JCI83185
   PubMed Web of Science ®Google Scholar
• Ly S, Didiot M-C, Ferguson CM, et al. Mutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains. Brain Commun. 2022;4:fcac248. doi: 10.1093/braincomms/fcac248
   PubMedGoogle Scholar
• Morelli KH, Wu Q, Gosztyla ML, et al. An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models. Nat Neurosci. 2023;26(1):27–38. doi: 10.1038/s41593-022-01207-1
   PubMed Web of Science ®Google Scholar
• Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79(3):416–438. doi: 10.1016/j.neuron.2013.07.033
   PubMed Web of Science ®Google Scholar
• van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084–2098. doi: 10.1016/S0140-6736(17)31287-4
   PubMed Web of Science ®Google Scholar
• Cividini C, Basaia S, Spinelli EG, et al. Amyotrophic lateral sclerosis–frontotemporal dementia. Neurology. 2021;98(4):e402–415. doi: 10.1212/WNL.0000000000013123
   Google Scholar
• Olney NT, Spina S, Miller BL. Frontotemporal Dementia. Neurol Clin. 2017;35(2):339–374. doi: 10.1016/j.ncl.2017.01.008
   PubMed Web of Science ®Google Scholar
• Ferrari R, Kapogiannis D, Huey ED, et al. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 2011;8(3):273–294. doi: 10.2174/156720511795563700
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol. 2005;64(8):730–739. doi: 10.1097/01.jnen.0000174335.27708.0a
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133. doi: 10.1126/science.1134108
   PubMed Web of Science ®Google Scholar
• Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–611. doi: 10.1016/j.bbrc.2006.10.093
   PubMed Web of Science ®Google Scholar
• Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227–240. doi: 10.2353/ajpath.2007.070182
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319(5870):1668–1672. doi: 10.1126/science.1154584
   PubMed Web of Science ®Google Scholar
• Purice MD, Taylor JP. Linking hnRNP function to ALS and FTD pathology. Front Neurosci. 2018;12:326. doi:10.3389/fnins.2018.00326
   PubMed Web of Science ®Google Scholar
• Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132(11):2922–2931. doi: 10.1093/brain/awp214
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9(10):995–1007. doi: 10.1016/S1474-4422(10)70195-2
   PubMed Web of Science ®Google Scholar
• Gitler AD, Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion. 2011;5(3):179–187. doi: 10.4161/pri.5.3.17230
   PubMed Web of Science ®Google Scholar
• Couthouis J, Hart MP, Shorter J, et al. A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci, USA. 2011;108(52):20881–20890. doi: 10.1073/pnas.1109434108
   PubMed Web of Science ®Google Scholar
• Sun Z, Diaz Z, Fang X, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 2011;9(4):e1000614. doi: 10.1371/journal.pbio.1000614
   PubMed Web of Science ®Google Scholar
• Couthouis J, Hart MP, Erion R, et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet. 2012;21(13):2899–2911. doi: 10.1093/hmg/dds116
   PubMed Web of Science ®Google Scholar
• Daigle JG, Lanson NA, Smith RB, et al. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet. 2013;22(6):1193–1205. doi: 10.1093/hmg/dds526
   PubMed Web of Science ®Google Scholar
• Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474(8):1417–1438. doi: 10.1042/BCJ20160499
   PubMed Web of Science ®Google Scholar
• DeJesus-Hernandez M, Mackenzie I, Boeve B, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–256. doi: 10.1016/j.neuron.2011.09.011
   PubMed Web of Science ®Google Scholar
• Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–268. doi: 10.1016/j.neuron.2011.09.010
   PubMed Web of Science ®Google Scholar
• Frottin F, Pérez-Berlanga M, Hartl FU, et al. Multiple pathways of toxicity induced by C9orf72 dipeptide repeat aggregates and G4C2 RNA in a cellular model. Elife. 2021;10. doi: 10.7554/eLife.62718
   PubMed Web of Science ®Google Scholar
• Jovicic A, Mertens J, Boeynaems S, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat Neurosci. 2015;18(9):1226–1229. doi: 10.1038/nn.4085
   PubMed Web of Science ®Google Scholar
• Freibaum BD, Lu Y, Lopez-Gonzalez R, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525(7567):129–133. doi: 10.1038/nature14974
   PubMed Web of Science ®Google Scholar
• Balendra R, Isaacs AM. C9orf72-mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol. 2018;14(9):544–558. doi: 10.1038/s41582-018-0047-2
   PubMed Web of Science ®Google Scholar
• Shi Y, Lin S, Staats KA, et al. Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med. 2018;24(3):313–325. doi: 10.1038/nm.4490
   PubMed Web of Science ®Google Scholar
• Li J, Lim RG, Kaye JA, et al. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. iScience. 2021;24(11):103221. doi: 10.1016/j.isci.2021.103221
   PubMed Web of Science ®Google Scholar
• Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol. 2012;11(3):232–240. doi: 10.1016/S1474-4422(12)70014-5
   PubMed Web of Science ®Google Scholar
• Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323–330. doi: 10.1016/S1474-4422(12)70043-1
   PubMed Web of Science ®Google Scholar
• Umoh ME, Fournier C, Li Y, et al. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87(10):1024–1030. doi: 10.1212/WNL.0000000000003067
   PubMed Web of Science ®Google Scholar
• King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61–80. doi:10.1016/j.brainres.2012.01.016
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang P-W, Pham J, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415–428. doi: 10.1016/j.neuron.2013.10.015
   PubMed Web of Science ®Google Scholar
• Lee YB, Chen H-J, Peres J, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5(5):1178–1186. doi: 10.1016/j.celrep.2013.10.049
   PubMed Web of Science ®Google Scholar
• Mori K, Lammich S, Mackenzie IRA, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathol. 2013;125(3):413–423. doi: 10.1007/s00401-013-1088-7
   PubMed Web of Science ®Google Scholar
• Conlon EG, Lu L, Sharma A, et al. The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. Elife. 2016;5. doi: 10.7554/eLife.17820
   PubMed Web of Science ®Google Scholar
• Lee KH, Zhang P, Kim HJ, et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167(3):774–788.e717. doi: 10.1016/j.cell.2016.10.002
   PubMed Web of Science ®Google Scholar
• Boeynaems S, Bogaert E, Kovacs D, et al. Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol Cell. 2017;65(6):1044–1055.e1045. doi: 10.1016/j.molcel.2017.02.013
   PubMed Web of Science ®Google Scholar
• Yin S, Lopez-Gonzalez R, Kunz RC, et al. Evidence that C9ORF72 dipeptide repeat proteins associate with U2 snRNP to cause Mis-splicing in ALS/FTD patients. Cell Rep. 2017;19(11):2244–2256. doi: 10.1016/j.celrep.2017.05.056
   PubMed Web of Science ®Google Scholar
• Lu L, Zheng L, Viera L, et al. Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression. J Neurosci. 2007;27(30):7929–7938. doi: 10.1523/JNEUROSCI.1877-07.2007
   PubMed Web of Science ®Google Scholar
• Lu L, Wang S, Zheng L, et al. Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters hu antigen R (HuR) and TIA-1-related protein (TIAR): implications for impaired post-transcriptional regulation of vascular endothelial growth factor. J Biol Chem. 2009;284(49):33989–33998. doi: 10.1074/jbc.M109.067918
   PubMed Web of Science ®Google Scholar
• Da Ros M, Deol HK, Savard A, et al. Wild-type and mutant SOD1 localizes to RNA-rich structures in cells and mice but does not bind RNA. J Neurochem. 2021;156(4):524–538. doi: 10.1111/jnc.15126
   PubMed Web of Science ®Google Scholar
• Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364(6435):362. doi: 10.1038/364362c0
   PubMed Web of Science ®Google Scholar
• Chen H, Qian K, Du Z, et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14(6):796–809. doi: 10.1016/j.stem.2014.02.004
   PubMed Web of Science ®Google Scholar
• Menzies FM, Grierson AJ, Cookson MR, et al. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J Neurochem. 2002;82(5):1118–1128. doi: 10.1046/j.1471-4159.2002.01045.x
   PubMed Web of Science ®Google Scholar
• Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27(2):336–349. doi: 10.1038/sj.emboj.7601930
   PubMed Web of Science ®Google Scholar
• Blokhuis AM, Groen EJ, Koppers M, et al. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125(6):777–794. doi: 10.1007/s00401-013-1125-6
   PubMed Web of Science ®Google Scholar
• Kim G, Gautier O, Tassoni-Tsuchida E, et al. ALS genetics: gains, losses, and implications for future therapies. Neuron. 2020;108(5):822–842. doi: 10.1016/j.neuron.2020.08.022
   PubMed Web of Science ®Google Scholar
• Xue YC, Ng CS, Xiang P, et al. Dysregulation of RNA-Binding Proteins in Amyotrophic Lateral Sclerosis. Front Mol Neurosci. 2020;13:78. doi: 10.3389/fnmol.2020.00078
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu S, Liu G, et al. ALS-associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet. 2013;9(10):e1003895. doi: 10.1371/journal.pgen.1003895
   PubMed Web of Science ®Google Scholar
• Coady TH, Manley JL. ALS mutations in TLS/FUS disrupt target gene expression. Genes Dev. 2015;29(16):1696–1706. doi: 10.1101/gad.267286.115
   PubMed Web of Science ®Google Scholar
• Hans F, Glasebach H, Kahle PJ. Multiple distinct pathways lead to hyperubiquitylated insoluble TDP-43 protein independent of its translocation into stress granules. J Biol Chem. 2020;295(3):673–689. doi: 10.1016/S0021-9258(17)49926-1
   PubMed Web of Science ®Google Scholar
• Humphrey J, Birsa N, Milioto C, et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 2020;48(12):6889–6905. doi: 10.1093/nar/gkaa410
   PubMed Web of Science ®Google Scholar
• Brown AL, Wilkins OG, Keuss MJ, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131–137. doi: 10.1038/s41586-022-04436-3
   PubMed Web of Science ®Google Scholar
• Ma XR, Prudencio M, Koike Y, et al. TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A. Nature. 2022;603(7899):124–130. doi: 10.1038/s41586-022-04424-7
   PubMed Web of Science ®Google Scholar
• Koike Y, Pickles S, Estades Ayuso V, et al. TDP-43 and other hnRNPs regulate cryptic exon inclusion of a key ALS/FTD risk gene, UNC13A. PLoS Biol. 2023;21(3):e3002028. doi: 10.1371/journal.pbio.3002028
   PubMed Web of Science ®Google Scholar
• Scekic-Zahirovic J, Sendscheid O, El Oussini H, et al. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss. EMBO J. 2016;35(10):1077–1097. doi: 10.15252/embj.201592559
   PubMed Web of Science ®Google Scholar
• Korobeynikov VA, Lyashchenko AK, Blanco-Redondo B, et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat Med. 2022;28(1):104–116. doi: 10.1038/s41591-021-01615-z
   PubMed Web of Science ®Google Scholar
• An H, Litscher G, Watanabe N, et al. ALS-linked cytoplasmic FUS assemblies are compositionally different from physiological stress granules and sequester hnRNPA3, a novel modifier of FUS toxicity. Neurobiol Dis. 2022;162:105585. doi: 10.1016/j.nbd.2021.105585
   PubMed Web of Science ®Google Scholar
• Jun MH, Ryu H-H, Jun Y-W, et al. Sequestration of PRMT1 and Nd1-L mRNA into ALS-linked FUS mutant R521C-positive aggregates contributes to neurite degeneration upon oxidative stress. Sci Rep. 2017;7(1):40474. doi: 10.1038/srep40474
   PubMedGoogle Scholar
• Tsai YL, Coady TH, Lu L, et al. ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. Genes Dev. 2020;34(11–12):785–805. doi: 10.1101/gad.335836.119
   PubMed Web of Science ®Google Scholar
• Nag N, Tripathi T. Mislocalization of Nup62 contributes to TDP-43 proteinopathy in ALS/FTLD. ACS Chem Neurosci. 2022;13(17):2544–2546. doi: 10.1021/acschemneuro.2c00480
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208–1211. doi: 10.1126/science.1165942
   PubMed Web of Science ®Google Scholar
• Huang EJ, Zhang J, Geser F, et al. Extensive FUS-immunoreactive pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions. Brain Pathol. 2010;20(6):1069–1076. doi: 10.1111/j.1750-3639.2010.00413.x
   PubMed Web of Science ®Google Scholar
• Keller BA, Volkening K, Droppelmann CA, et al. Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol. 2012;124(5):733–747. doi: 10.1007/s00401-012-1035-z
   PubMed Web of Science ®Google Scholar
• Ader C, Frey S, Maas W, et al. Amyloid-like interactions within nucleoporin FG hydrogels. Proc Natl Acad Sci U S A. 2010;107(14):6281–6285. doi: 10.1073/pnas.0910163107
   PubMed Web of Science ®Google Scholar
• Shi KY, Mori E, Nizami ZF, et al. Toxic PRn poly-dipeptides encoded by the C9orf72 repeat expansion block nuclear import and export. Proc Natl Acad Sci U S A. 2017;114(7):E1111–E1117. doi: 10.1073/pnas.1620293114
   PubMed Web of Science ®Google Scholar
• Zhang YJ, Gendron TF, Grima JC, et al. C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat Neurosci. 2016;19(5):668–677. doi: 10.1038/nn.4272
   PubMed Web of Science ®Google Scholar
• Lin Y, Mori E, Kato M, et al. Toxic PR Poly-Dipeptides Encoded by the C9orf72 repeat expansion target LC domain polymers. Cell. 2016;167(3):789–802.e712. doi: 10.1016/j.cell.2016.10.003
   PubMed Web of Science ®Google Scholar
• McGoldrick P, Lau A, You Z, et al. Loss of C9orf72 perturbs the Ran-GTPase gradient and nucleocytoplasmic transport, generating compositionally diverse importin β-1 granules. Cell Rep. 2023;42:112134. doi:10.1016/j.celrep.2023.112134
   PubMed Web of Science ®Google Scholar
• Zhong Y, Wang J, Henderson MJ, et al. Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. Elife. 2017;6. doi: 10.7554/eLife.23759
   Web of Science ®Google Scholar
• Gertz B, Wong M, Martin LJ. Nuclear localization of human SOD1 and mutant SOD1-specific disruption of survival motor neuron protein complex in transgenic amyotrophic lateral sclerosis mice. J Neuropathol Exp Neurol. 2012;71(2):162–177. doi: 10.1097/NEN.0b013e318244b635
   PubMed Web of Science ®Google Scholar
• Shang J, Yamashita T, Nakano Y, et al. Aberrant distributions of nuclear pore complex proteins in ALS mice and ALS patients. Neuroscience. 2017;350:158–168. doi: 10.1016/j.neuroscience.2017.03.024
   PubMed Web of Science ®Google Scholar
• Nonaka T, Masuda-Suzukake M, Hosokawa M, et al. C9ORF72 dipeptide repeat poly-GA inclusions promote intracellular aggregation of phosphorylated TDP-43. Hum Mol Genet. 2018;27(15):2658–2670. doi: 10.1093/hmg/ddy174
   PubMed Web of Science ®Google Scholar
• Niaki AG, Sarkar J, Cai X, et al. Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-Linked FUS mutations. Mol Cell. 2020;77(1):82–94 e84. doi: 10.1016/j.molcel.2019.09.022
   PubMed Web of Science ®Google Scholar
• Gonzalez A, Mannen T, Çağatay T, et al. Mechanism of karyopherin-β2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X). Sci Rep. 2021;11(1):3754. doi: 10.1038/s41598-021-83196-y
   PubMed Web of Science ®Google Scholar
• Conte A, Lattante S, Zollino M, et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul Disord. 2012;22(1):73–75. doi: 10.1016/j.nmd.2011.08.003
   PubMed Web of Science ®Google Scholar
• Sharma A, Lyashchenko AK, Lu L, et al. ALS-associated mutant FUS induces selective motor neuron degeneration through toxic gain of function. Nat Commun. 2016;7(1):10465. doi: 10.1038/ncomms10465
   PubMedGoogle Scholar
• Corcia P, Danel V, Lacour A, et al. A novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3–4):298–301. doi: 10.1080/21678421.2016.1265564
   PubMed Web of Science ®Google Scholar
• Zhou B, Wang H, Cai Y, et al. FUS P525L mutation causing amyotrophic lateral sclerosis and movement disorders. Brain Behav. 2020;10(6):e01625. doi: 10.1002/brb3.1625
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Warlick C, Coyne AN. Highly variable molecular signatures of TDP-43 loss of function are associated with nuclear pore complex injury in a population study of sporadic ALS patient iPsns. bioRxiv. 2023.
   Google Scholar
• Megat S, Mora N, Sanogo J, et al. Integrative genetic analysis illuminates ALS heritability and identifies risk genes. Nat Commun. 2023;14(1):342. doi: 10.1038/s41467-022-35724-1
   PubMed Web of Science ®Google Scholar
• Kaneb HM, Folkmann AW, Belzil VV, et al. Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum Mol Genet. 2015;24(5):1363–1373. doi: 10.1093/hmg/ddu545
   PubMed Web of Science ®Google Scholar
• van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636–1648. doi: 10.1038/s41588-021-00973-1
   PubMed Web of Science ®Google Scholar
• Workman MJ, Lim RG, Wu J, et al. Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects. Neuron. 2023;111(8):1191–1204.e1195. doi: 10.1016/j.neuron.2023.01.010
   PubMed Web of Science ®Google Scholar
• Wu CH, Fallini C, Ticozzi N, et al. Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012;488(7412):499–503. doi: 10.1038/nature11280
   PubMed Web of Science ®Google Scholar
• Smith BN, Ticozzi N, Fallini C, et al. Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron. 2014;84(2):324–331. doi: 10.1016/j.neuron.2014.09.027
   PubMed Web of Science ®Google Scholar
• Nicolas A, Kenna KP, Renton AE, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97(6):1268–1283.e6. doi: 10.1016/j.neuron.2018.02.027
   PubMed Web of Science ®Google Scholar
• Baron DM, Fenton AR, Saez-Atienzar S, et al. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 2022;39(1):110598. doi: 10.1016/j.celrep.2022.110598
   PubMed Web of Science ®Google Scholar
• Tran D, Chalhoub A, Schooley A, et al. A mutation in VAPB that causes amyotrophic lateral sclerosis also causes a nuclear envelope defect. J Cell Sci. 2012;125:2831–2836. doi:10.1242/jcs.102111
   PubMed Web of Science ®Google Scholar
• James C, Müller M, Goldberg MW, et al. Proteomic mapping by rapamycin-dependent targeting of APEX2 identifies binding partners of VAPB at the inner nuclear membrane. J Biol Chem. 2019;294(44):16241–16254. doi: 10.1074/jbc.RA118.007283
   PubMed Web of Science ®Google Scholar
• Tullio-Pelet A, Salomon R, Hadj-Rabia S, et al. Mutant WD-repeat protein in triple-A syndrome. Nat Genet. 2000;26(3):332–335. doi: 10.1038/81642
   PubMed Web of Science ®Google Scholar
• Handschug K, Sperling S, Yoon SJ, et al. Triple a syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet. 2001;10(3):283–290. doi: 10.1093/hmg/10.3.283
   PubMed Web of Science ®Google Scholar
• Huebner A, Kaindl AM, Knobeloch KP, et al. The triple a syndrome is due to mutations in ALADIN, a novel member of the nuclear pore complex. Endocr Res. 2004;30(4):891–899. doi: 10.1081/ERC-200044138
   PubMed Web of Science ®Google Scholar
• Cronshaw JM, Matunis MJ. The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome. Proc Natl Acad Sci U S A. 2003;100(10):5823–5827. doi: 10.1073/pnas.1031047100
   PubMed Web of Science ®Google Scholar
• Nousiainen HO, Kestilä M, Pakkasjärvi N, et al. Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat Genet. 2008;40(2):155–157. doi: 10.1038/ng.2007.65
   PubMed Web of Science ®Google Scholar
• Paakkola T, Vuopala K, Kokkonen H, et al. A homozygous I684T in GLE1 as a novel cause of arthrogryposis and motor neuron loss. Clin Genet. 2018;93(1):173–177. doi: 10.1111/cge.13086
   PubMed Web of Science ®Google Scholar
• Smith C, Parboosingh JS, Boycott KM, et al. Expansion of the GLE1-associated arthrogryposis multiplex congenita clinical spectrum. Clin Genet. 2017;91(3):426–430. doi: 10.1111/cge.12876
   PubMed Web of Science ®Google Scholar
• Bonnin E, Cabochette P, Filosa A, et al. Biallelic mutations in nucleoporin NUP88 cause lethal fetal akinesia deformation sequence. PLoS Genet. 2018;14(12):e1007845. doi: 10.1371/journal.pgen.1007845
   PubMed Web of Science ®Google Scholar
• Shamseldin HE, Makhseed N, Ibrahim N, et al. NUP214 deficiency causes severe encephalopathy and microcephaly in humans. Hum Genet. 2019;138(3):221–229. doi: 10.1007/s00439-019-01979-w
   PubMed Web of Science ®Google Scholar
• Fichtman B, Harel T, Biran N, et al. Pathogenic variants in NUP214 cause “plugged” nuclear pore channels and acute febrile encephalopathy. Am J Hum Genet. 2019;105(1):48–64. doi: 10.1016/j.ajhg.2019.05.003
   PubMed Web of Science ®Google Scholar
• Farooqui S, Narayanan DL, Mascarenhas S, et al. c.202_204del in NUP214 causes late onset form of febrile encephalopathy. Am J Med Genet A. 2024. doi:10.1002/ajmg.a.63529.
   PubMed Web of Science ®Google Scholar
• Neilson DE, Adams MD, Orr CMD, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009;84(1):44–51. doi: 10.1016/j.ajhg.2008.12.009
   PubMed Web of Science ®Google Scholar
• Shibata A, Kasai M, Hoshino A, et al. RANBP2 mutation causing autosomal dominant acute necrotizing encephalopathy attenuates its interaction with COX11. Neurosci Lett. 2021;763:136173. doi:10.1016/j.neulet.2021.136173
   PubMed Web of Science ®Google Scholar
• Deshmukh P, Singh A, Khuperkar D, et al. Acute necrotizing encephalopathy-linked mutations in Nup358 impair interaction of Nup358 with TNRC6/GW182 and miRNA function. Biochem Biophys Res Commun. 2021;559:230–237. doi:10.1016/j.bbrc.2021.04.027
   PubMed Web of Science ®Google Scholar
• Braun DA, Lovric S, Schapiro D, et al. Mutations in multiple components of the nuclear pore complex cause nephrotic syndrome. J Clin Invest. 2018;128(10):4313–4328. doi: 10.1172/JCI98688
   PubMed Web of Science ®Google Scholar
• Miyake N, Tsukaguchi H, Koshimizu E, et al. Biallelic mutations in nuclear pore complex subunit nup107 cause early-childhood-onset steroid-resistant nephrotic syndrome. Am J Hum Genet. 2015;97(4):555–566. doi: 10.1016/j.ajhg.2015.08.013
   PubMed Web of Science ®Google Scholar
• Rosti RO, Sotak BN, Bielas SL, et al. Homozygous mutation in NUP107 leads to microcephaly with steroid-resistant nephrotic condition similar to Galloway-Mowat syndrome. J Med Genet. 2017;54(6):399–403. doi: 10.1136/jmedgenet-2016-104237
   PubMed Web of Science ®Google Scholar
• Zhao F, Zhu J-Y, Richman A, et al. Mutations in NUP160 Are Implicated in Steroid-Resistant Nephrotic Syndrome. J Am Soc Nephrol. 2019;30(5):840–853. doi: 10.1681/ASN.2018080786
   PubMed Web of Science ®Google Scholar
• Braun DA, Sadowski CE, Kohl S, et al. Mutations in nuclear pore genes NUP93, NUP205 and XPO5 cause steroid-resistant nephrotic syndrome. Nat Genet. 2016;48(4):457–465. doi: 10.1038/ng.3512
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen S, Yoo S, et al. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell. 2008;135(6):1017–1027. doi: 10.1016/j.cell.2008.10.022
   PubMed Web of Science ®Google Scholar
• Sandestig A, Engström K, Pepler A, et al. Biallelic loss of function may underlie a new syndrome: nucleoporin 188 insufficiency syndrome? Mol Syndromol. 2020;10(6):313–319. doi: 10.1159/000504818
   PubMed Web of Science ®Google Scholar
• Muir AM, Cohen JL, Sheppard SE, et al. Bi-allelic loss-of-function variants in NUP188 cause a recognizable syndrome characterized by neurologic, ocular, and cardiac abnormalities. Am J Hum Genet. 2020;106(5):623–631. doi: 10.1016/j.ajhg.2020.03.009
   PubMed Web of Science ®Google Scholar
• Harrer P, Schalk A, Shimura M, et al. Recessive NUP54 variants underlie early-onset dystonia with striatal lesions. Ann Neurol. 2023;93(2):330–335. doi: 10.1002/ana.26544
   PubMed Web of Science ®Google Scholar
• Basel-Vanagaite L, Muncher L, Straussberg R, et al. Mutated nup62 causes autosomal recessive infantile bilateral striatal necrosis. Ann Neurol. 2006;60(2):214–222. doi: 10.1002/ana.20902
   PubMed Web of Science ®Google Scholar
• Van Bergen NJ, Bell KM, Carey K, et al. Pathogenic variants in nucleoporin TPR (translocated promoter region, nuclear basket protein) cause severe intellectual disability in humans. Hum Mol Genet. 2022;31(3):362–375. doi: 10.1093/hmg/ddab248
   PubMed Web of Science ®Google Scholar
• Strauss M, Koehler K, Krumbholz M, et al. Triple a syndrome mimicking ALS. Amyotroph Lateral Scler. 2008;9(5):315–317. doi: 10.1080/17482960802259016
   PubMed Web of Science ®Google Scholar
• Vallet AE, Verschueren A, Petiot P, et al. Neurological features in adult Triple-A (Allgrove) syndrome. J Neurol. 2012;259(1):39–46. doi: 10.1007/s00415-011-6115-9
   PubMed Web of Science ®Google Scholar
• Vigano’ M, Mantero V, Basilico P, et al. Don’t forget Allgrove syndrome in adult patients as a bulbar-ALS mimicker. Neurol Sci. 2023;44:3703–3705. doi: 10.1007/s10072-023-06961-z.
   PubMed Web of Science ®Google Scholar
• Strauss KA, Gonzaga-Jauregui C, Brigatti KW, et al. Genomic diagnostics within a medically underserved population: efficacy and implications. Genet Med. 2018;20(1):31–41. doi: 10.1038/gim.2017.76
   PubMed Web of Science ®Google Scholar
• Consortium U, Martin M-J, Orchard S. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2023;51(D1):D523–D531. doi: 10.1093/nar/gkac1052
   PubMed Web of Science ®Google Scholar
• Tarazón E, Rivera M, Roselló-Lletí E, et al. Heart failure induces significant changes in nuclear pore complex of human cardiomyocytes. PLoS One. 2012;7(11):e48957. doi: 10.1371/journal.pone.0048957
   PubMed Web of Science ®Google Scholar
• Lai TH, Wu Y-Y, Wang Y-Y, et al. SEPT12–NDC1 Complexes Are Required for Mammalian Spermiogenesis. Int J Mol Sci. 2016;17(11):1911. doi: 10.3390/ijms17111911
   PubMed Web of Science ®Google Scholar
• Cipollini M, Luisi S, Piomboni P, et al. Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis. Fertil Steril. 2019;112(2):343–352.e341. doi: 10.1016/j.fertnstert.2019.04.011
   PubMed Web of Science ®Google Scholar
• Qiao W, Han Y, Jin W, et al. Overexpression and biological function of TMEM48 in non-small cell lung carcinoma. Tumour Biol. 2016;37(2):2575–2586. doi: 10.1007/s13277-015-4014-x
   PubMedGoogle Scholar
• Rodriguez-Bravo V, Pippa R, Song W-M, et al. Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import. Cell. 2018;174(5):1200–1215.e1220. doi: 10.1016/j.cell.2018.07.015
   PubMed Web of Science ®Google Scholar
• Gu Q, Hou W, Liu H, et al. NUP210 and MicroRNA-22 modulate fas to elicit HeLa cell cycle arrest. Yonsei Med J. 2020;61(5):371–381. doi: 10.3349/ymj.2020.61.5.371
   PubMed Web of Science ®Google Scholar
• Guan L, Zhang L, Wang T, et al. POM121 promotes proliferation and metastasis in non-small-cell lung cancer through TGF-β/SMAD and PI3K/AKT pathways. Cancer Biomark. 2021;32(3):293–302. doi: 10.3233/CBM-210001
   PubMed Web of Science ®Google Scholar
• Hong SH, Son KH, Ha SY, et al. Nucleoporin 210 serves a key scaffold for SMARCB1 in liver cancer. Cancer Res. 2021;81(2):356–370. doi: 10.1158/0008-5472.CAN-20-0568
   PubMed Web of Science ®Google Scholar
• Bindra D, Mishra RK. In pursuit of distinctiveness: transmembrane nucleoporins and their disease associations. Front Oncol. 2021;11:784319. doi:10.3389/fonc.2021.784319
   PubMed Web of Science ®Google Scholar
• Wong X, Stewart CL. The laminopathies and the insights they provide into the structural and functional organization of the nucleus. Annu Rev Genom Hum Genet. 2020;21(1):263–288. doi: 10.1146/annurev-genom-121219-083616
   PubMedGoogle Scholar
• Han M, Zhao M, Cheng C, et al. Lamin a mutation impairs interaction with nucleoporin NUP155 and disrupts nucleocytoplasmic transport in atrial fibrillation. Hum Mutat. 2019;40(3):310–325. doi: 10.1002/humu.23691
   PubMed Web of Science ®Google Scholar
• Lussi YC, Hügi I, Laurell E, et al. The nucleoporin Nup88 is interacting with nuclear lamin A. Mol Biol Cell. 2011;22(7):1080–1090. doi: 10.1091/mbc.e10-05-0463
   PubMed Web of Science ®Google Scholar
• Bechert K, Lagos-Quintana M, Harborth J, et al. Effects of expressing lamin A mutant protein causing Emery-Dreifuss muscular dystrophy and familial partial lipodystrophy in HeLa cells. Exp Cell Res. 2003;286(1):75–86. doi: 10.1016/S0014-4827(03)00104-6
   PubMed Web of Science ®Google Scholar
• Dutta S, Das JK, Maganti L, et al. Skeletal muscle dystrophy mutant of lamin A alters the structure and dynamics of the Ig fold domain. Sci Rep. 2018;8(1):13793. doi: 10.1038/s41598-018-32227-2
   PubMedGoogle Scholar
• Méjat A, Misteli T. LINC complexes in health and disease. Nucleus. 2010;1(1):40–52. doi: 10.4161/nucl.1.1.10530
   PubMed Web of Science ®Google Scholar
• Liu Q, Pante N, Misteli T, et al. Functional association of Sun1 with nuclear pore complexes. J Cell Bio. 2007;178(5):785–798. doi: 10.1083/jcb.200704108
   PubMed Web of Science ®Google Scholar
• Smith MA, Blankman E, Jensen CC, et al. Nuclear pore complexes concentrate on Actin/LINC/Lamin nuclear lines in response to mechanical stress in a SUN1 dependent manner. Heliyon. 2022;8(12):e12147. doi: 10.1016/j.heliyon.2022.e12147
   PubMed Web of Science ®Google Scholar
• Meinke P, Mattioli E, Haque F, et al. Muscular dystrophy-associated SUN1 and SUN2 variants disrupt nuclear-cytoskeletal connections and myonuclear organization. PLoS Genet. 2014;10(9):e1004605. doi: 10.1371/journal.pgen.1004605
   PubMed Web of Science ®Google Scholar
• Li P, Meinke P, Huong LT, et al. Contribution of SUN1 mutations to the pathomechanism in muscular dystrophies. Hum Mutat. 2014;35(4):452–461. doi: 10.1002/humu.22504
   PubMed Web of Science ®Google Scholar
• Chen CY, Chi Y-H, Mutalif R, et al. Accumulation of the inner nuclear envelope protein Sun1 is pathogenic in progeric and dystrophic laminopathies. Cell. 2012;149(3):565–577. doi: 10.1016/j.cell.2012.01.059
   PubMed Web of Science ®Google Scholar
• Arii J, Maeda F, Maruzuru Y, et al. ESCRT-III controls nuclear envelope deformation induced by progerin. Sci Rep. 2020;10(1):18877. doi: 10.1038/s41598-020-75852-6
   PubMed Web of Science ®Google Scholar
• Shankar R, Lettman MM, Whisler W, et al. The ESCRT machinery directs quality control over inner nuclear membrane architecture. Cell Rep. 2022;38(3):110263. doi: 10.1016/j.celrep.2021.110263
   PubMed Web of Science ®Google Scholar
• Wu X, Kasper LH, Mantcheva RT, et al. Disruption of the FG nucleoporin NUP98 causes selective changes in nuclear pore complex stoichiometry and function. Proc Natl Acad Sci U S A. 2001;98(6):3191–3196. doi: 10.1073/pnas.051631598
   PubMed Web of Science ®Google Scholar
• Jevtić P, Schibler AC, Wesley CC, et al. The nucleoporin ELYS regulates nuclear size by controlling NPC number and nuclear import capacity. EMBO Rep. 2019;20(6). doi: 10.15252/embr.201847283
   PubMed Web of Science ®Google Scholar
• Sakuma S, Zhu EY, Raices M, et al. Loss of Nup210 results in muscle repair delays and age-associated alterations in muscle integrity. Life Sci Alliance. 2022;5(3):e202101216. doi: 10.26508/lsa.202101216
   PubMed Web of Science ®Google Scholar
• Cho KI, Yoon D, Qiu S, et al. Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes. Dis Model Mech. 2017;10(5):559–579. doi: 10.1242/dmm.027730
   PubMed Web of Science ®Google Scholar
• Zimmerli CE, Allegretti M, Rantos V, et al. Nuclear pores dilate and constrict in cellulo. Science. 2021;374(6573):eabd9776. doi: 10.1126/science.abd9776
   PubMed Web of Science ®Google Scholar
• Xu S, Zhang X, Liu C, et al. Role of mitochondria in neurodegenerative diseases: from an epigenetic perspective. Front Cell Dev Biol. 2021;9:688789. doi: 10.3389/fcell.2021.688789
   PubMed Web of Science ®Google Scholar
• Panagaki D, Croft JT, Keuenhof K, et al. Nuclear envelope budding is a response to cellular stress. Proc Natl Acad Sci, USA. 2021;118(30). doi: 10.1073/pnas.2020997118
   Web of Science ®Google Scholar
• Donnaloja F, Jacchetti E, Soncini M, et al. Mechanosensing at the nuclear envelope by nuclear pore complex stretch activation and its effect in physiology and pathology. Front Physiol. 2019;10:896. doi:10.3389/fphys.2019.00896
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Smith MA, Jensen CC, et al. Mechanical stress triggers nuclear remodeling and the formation of transmembrane actin nuclear lines with associated nuclear pore complexes. Mol Biol Cell. 2020;31(16):1774–1787. doi: 10.1091/mbc.E19-01-0027
   PubMed Web of Science ®Google Scholar
• Goelzer M, Goelzer J, Ferguson ML, et al. Nuclear envelope mechanobiology: linking the nuclear structure and function. Nucleus. 2021;12(1):90–114. doi: 10.1080/19491034.2021.1962610
   PubMed Web of Science ®Google Scholar
• Hocquemiller M, Giersch L, Audrain M, et al. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27(7):478–496. doi: 10.1089/hum.2016.087
   PubMed Web of Science ®Google Scholar
• Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med. 2021;8:809118. doi:10.3389/fmed.2021.809118
   Google Scholar
• Kuzmin DA, Shutova MV, Johnston NR, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20(3):173–174. doi: 10.1038/d41573-021-00017-7
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29(2):464–488. doi: 10.1016/j.ymthe.2020.12.007
   PubMed Web of Science ®Google Scholar
• Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet. 2011;20(4):681–693. doi: 10.1093/hmg/ddq514
   PubMed Web of Science ®Google Scholar
• Stevens D, Claborn MK, Gildon BL, et al. Onasemnogene Abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother. 2020;54(10):1001–1009. doi: 10.1177/1060028020914274
   PubMed Web of Science ®Google Scholar
• Huang Q, Chen AT, Chan KY, et al. Targeting AAV vectors to the central nervous system by engineering capsid–receptor interactions that enable crossing of the blood–brain barrier. PLoS Biol. 2023;21(7):e3002112. doi: 10.1371/journal.pbio.3002112
   PubMed Web of Science ®Google Scholar
• Bastos R, Lin A, Enarson M, et al. Targeting and function in mRNA export of nuclear pore complex protein Nup153. J Cell Bio. 1996;134(5):1141–1156. doi: 10.1083/jcb.134.5.1141
   PubMed Web of Science ®Google Scholar
• Boer J, Bonten-Surtel J, Grosveld G. Overexpression of the nucleoporin CAN/NUP214 induces growth arrest, nucleocytoplasmic transport defects, and apoptosis. Mol Cell Biol. 1998;18(3):1236–1247. doi: 10.1128/MCB.18.3.1236
   PubMed Web of Science ®Google Scholar
• Wu Z, Yang H, Colosi P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18(1):80–86. doi: 10.1038/mt.2009.255
   PubMed Web of Science ®Google Scholar
• Marrone L, Marchi PM, Azzouz M. Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders. Expert Opin Biol Ther. 2022;22(9):1–14. doi: 10.1080/14712598.2022.2012148
   PubMed Web of Science ®Google Scholar
• Nofrini V, Di Giacomo D, Mecucci C. Nucleoporin genes in human diseases. Eur J Hum Genet. 2016;24(10):1388–1395. doi: 10.1038/ejhg.2016.25
   PubMed Web of Science ®Google Scholar
• Talap J, Zhao J, Shen M, et al. Recent advances in therapeutic nucleic acids and their analytical methods. J Pharm Biomed Anal. 2021;206:114368. doi: 10.1016/j.jpba.2021.114368
   PubMed Web of Science ®Google Scholar
• Ori A, Banterle N, Iskar M, et al. Cell type-specific nuclear pores: a case in point for context-dependent stoichiometry of molecular machines. Mol Syst Biol. 2013;9(1):648. doi: 10.1038/msb.2013.4
   PubMedGoogle Scholar
• Fare CM, Shorter J. (Dis)Solving the problem of aberrant protein states. Dis Model Mech. 2021;14(5). doi: 10.1242/dmm.048983
   PubMed Web of Science ®Google Scholar
• Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals. 2008;16(1):63–74. doi: 10.1159/000109760
   PubMedGoogle Scholar
• Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475(7356):324–332. doi: 10.1038/nature10317
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Kwon YT. Protein quality control by molecular chaperones in neurodegeneration. Front Neurosci. 2017;11:185. doi:10.3389/fnins.2017.00185
   PubMed Web of Science ®Google Scholar
• Mann JR, Gleixner AM, Mauna JC, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102(2):321–338 e328. doi: 10.1016/j.neuron.2019.01.048
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Maeta K, Ding X, et al. Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice. Mol Ther Nucleic Acids. 2023;31:353–366. doi: 10.1016/j.omtn.2023.01.006
   PubMedGoogle Scholar
• McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128(8):3558–3567. doi: 10.1172/JCI99081
   PubMed Web of Science ®Google Scholar
• Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099–1110. doi: 10.1056/NEJMoa2204705
   PubMed Web of Science ®Google Scholar
• Odeh HM, Fare CM, Shorter J. Nuclear-import receptors counter deleterious phase transitions in neurodegenerative disease. J Mol Biol. 2022;434(1):167220. doi: 10.1016/j.jmb.2021.167220
   PubMed Web of Science ®Google Scholar
• Guo L, Fare CM, Shorter J. Therapeutic dissolution of aberrant phases by nuclear-import receptors. Trends Cell Biol. 2019;29(4):308–322. doi: 10.1016/j.tcb.2018.12.004
   PubMed Web of Science ®Google Scholar
• Robinson E, Shorter J, Guo L. Karyopherin-β2 inhibits and reverses aggregation and liquid-liquid phase separation of the ALS/FTD-Associated protein FUS. Bio Protoc. 2020;10(16):e3725. doi: 10.21769/BioProtoc.3725
   PubMed Web of Science ®Google Scholar
• Mizuguchi-Hata C, Ogawa Y, Oka M, et al. Quantitative regulation of nuclear pore complex proteins by O-GlcNAcylation. Biochim Biophys Acta. 2013;1833(12):2682–2689. doi: 10.1016/j.bbamcr.2013.06.008
   PubMed Web of Science ®Google Scholar
• Ruba A, Yang W. O-GlcNAc-ylation in the nuclear pore complex. Cell Mol Bioeng. 2016;9(2):227–233. doi: 10.1007/s12195-016-0440-0
   PubMed Web of Science ®Google Scholar
• Zhu Y, Liu T-W, Madden Z, et al. Post-translational O-GlcNAcylation is essential for nuclear pore integrity and maintenance of the pore selectivity filter. J Mol Cell Biol. 2016;8(1):2–16. doi: 10.1093/jmcb/mjv033
   PubMed Web of Science ®Google Scholar
• Yoo TY, Mitchison TJ. O-GlcNAc modification of nuclear pore complexes accelerates bidirectional transport. J Cell Bio. 2021;220(7). doi: 10.1083/jcb.202010141
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935–949. doi: 10.1038/nrd1549
   PubMed Web of Science ®Google Scholar
• Leman JK, Weitzner BD, Lewis SM, et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat Methods. 2020;17(7):665–680. doi: 10.1038/s41592-020-0848-2
   PubMed Web of Science ®Google Scholar
• Coyne AN, Rothstein JD. The ESCRT-III protein VPS4, but not CHMP4B or CHMP2B, is pathologically increased in familial and sporadic ALS neuronal nuclei. Acta Neuropathol Commun. 2021;9(1):127. doi: 10.1186/s40478-021-01228-0
   PubMed Web of Science ®Google Scholar
• Parkinson N, Ince PG, Smith MO, et al. ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B). Neurology. 2006;67(6):1074–1077. doi: 10.1212/01.wnl.0000231510.89311.8b
   PubMed Web of Science ®Google Scholar
• van der Zee J, Urwin H, Engelborghs S, et al. CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum Mol Genet. 2008;17(2):313–322. doi: 10.1093/hmg/ddm309
   PubMed Web of Science ®Google Scholar
• Cox LE, Ferraiuolo L, Goodall EF, et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One. 2010;5(3):e9872. doi: 10.1371/journal.pone.0009872
   PubMed Web of Science ®Google Scholar
• Isaacs AM, Johannsen P, Holm I, et al. Frontotemporal dementia caused by CHMP2B mutations. Curr Alzheimer Res. 2011;8(3):246–251. doi: 10.2174/156720511795563764
   PubMed Web of Science ®Google Scholar
• Clayton EL, Bonnycastle K, Isaacs AM, et al. A novel synaptopathy-defective synaptic vesicle protein trafficking in the mutant CHMP2B mouse model of frontotemporal dementia. J Neurochem. 2022;160(3):412–425. doi: 10.1111/jnc.15551
   PubMed Web of Science ®Google Scholar
• van Blitterswijk M, Vlam L, van Es MA, et al. Genetic overlap between apparently sporadic motor neuron diseases. PloS One. 2012;7(11):e48983. doi: 10.1371/journal.pone.0048983
   PubMed Web of Science ®Google Scholar
• Narain P, Pandey A, Gupta S, et al. Targeted next-generation sequencing reveals novel and rare variants in Indian patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2018;71:.e265.269–.e265.214. doi: 10.1016/j.neurobiolaging.2018.05.012
   Web of Science ®Google Scholar
• Urwin H, Authier A, Nielsen JE, et al. Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Hum Mol Genet. 2010;19(11):2228–2238. doi: 10.1093/hmg/ddq100
   PubMed Web of Science ®Google Scholar
• Ghazi-Noori S, Froud KE, Mizielinska S, et al. Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain. 2012;135(3):819–832. doi: 10.1093/brain/aws006
   PubMed Web of Science ®Google Scholar
• Clayton EL, Mizielinska S, Edgar JR, et al. Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathol. 2015;130(4):511–523. doi: 10.1007/s00401-015-1475-3
   PubMed Web of Science ®Google Scholar
• Clayton EL, Milioto C, Muralidharan B, et al. Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown. Brain. 2018;141(12):3428–3442. doi: 10.1093/brain/awy284
   PubMedGoogle Scholar
• Prissette M, Fury W, Koss M, et al. Disruption of nuclear envelope integrity as a possible initiating event in tauopathies. Cell Rep. 2022;40(8):111249. doi: 10.1016/j.celrep.2022.111249
   PubMed Web of Science ®Google Scholar
• Gu M, LaJoie D, Chen OS, et al. LEM2 recruits CHMP7 for ESCRT-mediated nuclear envelope closure in fission yeast and human cells. Proc Natl Acad Sci U S A. 2017;114(11):E2166–E2175. doi: 10.1073/pnas.1613916114
   PubMed Web of Science ®Google Scholar
• Nim S, O’Hara DM, Corbi-Verge C, et al. Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease. Nat Commun. 2023;14(1):2150. doi: 10.1038/s41467-023-37464-2
   PubMed Web of Science ®Google Scholar
• Baron O, Boudi A, Dias C, et al. Stall in canonical autophagy-lysosome pathways prompts nucleophagy-based nuclear breakdown in neurodegeneration. Curr Biol. 2017;27(23):3626–3642.e3626. doi: 10.1016/j.cub.2017.10.054
   PubMed Web of Science ®Google Scholar
• Malik BR, Maddison DC, Smith GA, et al. Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Mol Brain. 2019;12(1):100. doi: 10.1186/s13041-019-0504-x
   PubMed Web of Science ®Google Scholar
• Cunningham KM, Maulding K, Ruan K, et al. TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. Elife. 2020;9. doi: 10.7554/eLife.59419
   Web of Science ®Google Scholar
• Lin C, Wu H, Weng E, et al. Fluvoxamine restores TFEB-mediated autophagy through sigma-1R-controlled POM121 expression. Res Square. 2023 doi: 10.1007/s12035-023-03885-9
   Google Scholar
• Lee PT, Liévens J-C, Wang S-M, et al. Sigma-1 receptor chaperones rescue nucleocytoplasmic transport deficit seen in cellular and Drosophila ALS/FTD models. Nat Commun. 2020;11(1):5580. doi: 10.1038/s41467-020-19396-3
   PubMed Web of Science ®Google Scholar
• Estévez-Silva HM, et al. Pridopidine promotes synaptogenesis and reduces spatial memory deficits in the Alzheimer’s disease APP/PS1 mouse model. Neurotherapeutics. 2022;19:1566–1587. doi: 10.1007/s13311-022-01280-1
   PubMed Web of Science ®Google Scholar
• Francardo V, et al. Pridopidine induces functional neurorestoration via the sigma-1 receptor in a mouse model of Parkinson’s disease. Neurotherapeutics. 2019;16:465–479. doi: 10.1007/s13311-018-00699-9
   PubMed Web of Science ®Google Scholar
• Eddings CR, Arbez N, Akimov S, et al. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019;129:118–129. doi: 10.1016/j.nbd.2019.05.009
   PubMed Web of Science ®Google Scholar
• Madeira F, Pearce M, Tivey ARN, et al. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic Acids Res. 2022;50(W1):W276–W279. doi: 10.1093/nar/gkac240
   PubMed Web of Science ®Google Scholar
• Makałowski W, Zhang J, Boguski MS. Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res. 1996;6(9):846–857. doi: 10.1101/gr.6.9.846
   PubMed Web of Science ®Google Scholar
• Grenier K, Kao J, Diamandis P. Three-dimensional modeling of human neurodegeneration: brain organoids coming of age. Mol Psychiatry. 2020;25(2):254–274. doi: 10.1038/s41380-019-0500-7
   PubMed Web of Science ®Google Scholar
• Mohamed MS, Hazawa M, Kobayashi A, et al. Spatiotemporally tracking of nano-biofilaments inside the nuclear pore complex core. Biomaterials. 2020;256:120198. doi: 10.1016/j.biomaterials.2020.120198
   PubMed Web of Science ®Google Scholar
• Venkataraman L, Fair SR, McElroy CA, et al. Modeling neurodegenerative diseases with cerebral organoids and other three-dimensional culture systems: focus on Alzheimer’s disease. Stem Cell Rev And Rep. 2022;18(2):696–717. doi: 10.1007/s12015-020-10068-9
   PubMed Web of Science ®Google Scholar